TCRαβ+CD4-CD8- T细胞在牙周炎中的治疗潜力
本研究比较了牙周炎患者与健康人牙龈组织中TCRαβ+双阴性T(DNT)细胞频率,发现患者显著降低;在小鼠模型中治疗性给予TCRαβ+ DNT细胞可减少牙槽骨吸收和炎症标志物,低细胞剂量效果最显著,并证实穿孔素是关键效应分子。
要点
- 牙周炎患者牙龈组织中TCRαβ+ DNT细胞频率较健康人显著降低。
- 小鼠模型中TCRαβ+ DNT细胞治疗减少牙槽骨吸收和炎症生物标志物。
- 穿孔素在TCRαβ+ DNT细胞调控牙周炎症中起关键作用。
核心结论
- TCRαβ+ DNT细胞治疗可能是牙周炎的一种有前景的新型治疗策略。
研究设计与样本
- 研究比较了牙周炎患者与健康个体牙龈组织中TCRαβ+ DNT细胞的频率。
- 采用小鼠模型进行TCRαβ+ DNT细胞治疗实验,并进行组织学、基因表达和转录组分析。
- 开展体外和体内实验验证穿孔素在TCRαβ+ DNT细胞中的作用。
主要发现
- 牙周炎患者牙龈组织中TCRαβ+ DNT细胞频率较健康个体显著降低。
- 小鼠模型中TCRαβ+ DNT细胞治疗减少牙槽骨吸收和炎症生物标志物,低细胞剂量效果最显著。
- 组织学和基因表达分析显示促炎细胞因子表达水平显著减弱。
- 转录组分析揭示中性粒细胞活化和白细胞介素-17信号通路下调。
- 体外和体内实验表明穿孔素对TCRαβ+ DNT细胞调控牙周炎症和防止牙槽骨丢失至关重要。
临床怎么用
- TCRαβ+ DNT细胞疗法可能为牙周炎提供新的免疫治疗思路,尤其低剂量方案值得关注。
- 穿孔素是TCRαβ+ DNT细胞发挥保护作用的关键分子,可作为潜在疗效标志。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Periodontitis, a pervasive chronic inflammatory disorder, is distinguished by the progressive degradation of periodontal tissues and alveolar bone. Despite remarkable progress in understanding the pathogenesis of periodontitis, the involvement of TCRαβ+CD4-CD8- T cells, also known as double-negative T (DNT) cells, in the pathophysiology of this disease has not been thoroughly investigated. In this study, we observed a significant reduction in the frequency of TCRαβ+ DNT cells within the gingival tissues of patients afflicted with periodontitis when compared with healthy individuals. Employing a murine model, we demonstrated that the therapeutic administration of TCRαβ+ DNT cells resulted in a reduction of alveolar bone resorption and a decrease in inflammatory biomarkers, with the most significant effects observed at lower cell doses. Histological examination and gene expression analysis revealed a notable attenuation in the expression levels of proinflammatory cytokines. Furthermore, transcriptomic profiling elucidated the downregulation of pathways associated with neutrophil activation and interleukin-17 signaling, which are critical in the inflammatory cascade of periodontitis. Both in vitro and in vivo experiments underscored the pivotal role of perforin in TCRαβ+ DNT cells, which is essential for modulating periodontal inflammation and preventing alveolar bone loss. Collectively, our findings suggest that TCRαβ+ DNT cell therapy may represent a promising novel therapeutic strategy for periodontitis, providing valuable insights into the development of innovative treatment modalities for this prevalent oral health condition.
引用
- Ma LS, Shen ZS, Huang SY, et al. Therapeutic Potential of TCRαβ+CD4-CD8- T Cells in Periodontitis. J Dent Res. 2025. PMID: 40926354. doi:10.1177/00220345251362744
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。